Stock Trading Canary

Built: 2026-10-19T16:02:49+00:00 · 中文

← South Korea

SOUTH KOREA · OPENDART

Onconic Therapeutics Inc.

온코닉테라퓨틱스 · 476060 · KOSDAQ · Healthcare · Drug Manufacturers—Specialty & Generic

Score

Not ranked: no net buying on the exchange by an individual insider in the last 180 days.

Insider timeline

No purchase in the last 180 days; 2 insiders sold.

Cha Hyeon-juCha Hyeon-juMember of the executive committeeExecutiveJohn KimJohn KimChief Executive OfficerCEO / chair2026-04-24 · Cha Hyeon-ju · sale · 444,160,000 KRW2026-06-02 · John Kim · sale · 501,754,966 KRW2026-06-24 · John Kim · sale · 1,159,166,931 KRW2026-06-25 · John Kim · sale · 184,167,900 KRW2026-06-29 · John Kim · sale · 1,199,359,067 KRW2026-06-30 · John Kim · sale · 271,483,200 KRWMayJunJulAugSepOct

Tap an item for what it means.

×A sale

A cross is one insider's sales on one day. People sell to pay tax, to cash in share awards or to hold less of one company, so a sale says less than a purchase does. When someone bought and sold on the same day, the cross sits beside the dot. The totals are under “Purchases against sales” below.

Blue line: this share's price, −38.4% over these six months

The closing price of each day, from 22,550.00 on 2026-04-21 to 13,900.00 on 2026-10-16. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.

Dashed line: the typical stock on the same exchange, −31.9%

Taken from the 1525 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share −38.4%, the typical one −31.9%, 6.5 points behind. It is not an index and not a comparison within one industry.

This company: insiders buying per month, last 12 months

Nov
Dec
1Jan
1Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct

Darker bars are inside the 180-day window above.

Who traded

InsiderRolePurchasesSalesBoughtFirst purchaseShare price since
Cha Hyeon-juExecutive—1———
John KimCEO / chair—5———

Insiders' buying price vs the latest close

Insiders paid 18,820.35 KRW a share on average (4 purchase lines, 1 buyer, 2026-01-13 – 2026-02-20). The close on 2026-10-16 was 26.1% below that price.

The latest purchase (2026-02-20) was at 19,078.00 KRW; the close was 27.1% below that price.

Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored.

Insider trades on the exchange

Purchases and sales on the exchange in the last 12 months. The filing gives the settlement date; the trade date is two trading days earlier.

Trade dateInsiderRoleTradeSharesPriceValueFiling
2026-06-30John KimCEOSold on the exchange19,962₩13,600₩271.5MDART ↗
2026-06-29John KimCEOSold on the exchange87,743₩13,669₩1.2BDART ↗
2026-06-25John KimCEOSold on the exchange12,300₩14,973₩184.2MDART ↗
2026-06-24John KimCEOSold on the exchange80,987₩14,313₩1.2BDART ↗
2026-06-02John KimCEOSold on the exchange28,577₩17,558₩501.8MDART ↗
2026-04-24Cha Hyeon-juManaging directorSold on the exchange20,000₩22,208₩444.2MDART ↗
2026-04-01Kim Jin-seongManaging directorSold on the exchange33,000₩22,253₩734.3MDART ↗
2026-02-20SHIN JONGKILSenior managing directorBought on the exchange11,032₩19,078₩210.5MDART ↗
2026-02-19SHIN JONGKILSenior managing directorBought on the exchange15,802₩18,295₩289.1MDART ↗
2026-02-13SHIN JONGKILSenior managing directorBought on the exchange27,184₩18,379₩499.6MDART ↗
2026-01-13SHIN JONGKILSenior managing directorBought on the exchange13,373₩20,126₩269.1MDART ↗
2025-12-26SHIN JONGKILSenior managing directorSold on the exchange218,026₩20,132₩4.4BDART ↗
2025-12-26SHIN JONGKILSenior managing directorSold on the exchange12,528₩21,551₩270.0MDART ↗
2025-12-26SHIN JONGKILSenior managing directorSold on the exchange218,026₩20,132₩4.4BDART ↗
2025-12-26SHIN JONGKILSenior managing directorSold on the exchange12,528₩21,551₩270.0MDART ↗
2025-12-26John KimCEOSold on the exchange120,000₩20,345₩2.4BDART ↗
2025-12-24John KimCEOSold on the exchange40,000₩18,907₩756.3MDART ↗
Other changes in holdings · 41

Option exercises, grants, new shares, inheritance, gifts, off-exchange trades and trades by companies and funds. Not counted in the score.

DateInsiderRoleReasonSharesFiling
2026-04-13Han Sang-cheolPresidentNew appointment(+)22,847DART ↗
2026-04-10John KimCEOExercise of appraisal rights(+)140,000DART ↗
2026-04-10Cha Hyeon-juManaging directorExercise of appraisal rights(+)90,000DART ↗
2026-04-10SHIN JONGKILSenior managing directorExercise of appraisal rights(+)130,000DART ↗
2026-04-10Kim Jin-seongManaging directorExercise of appraisal rights(+)72,000DART ↗
2026-01-02SHIN JONGKILSenior managing directorExercise of appraisal rights(+)131,974DART ↗
2026-01-02SHIN JONGKILSenior managing directorExercise of appraisal rights(+)131,974DART ↗
2026-01-02John KimCEOExercise of appraisal rights(+)260,000DART ↗
2025-11-04John KimCEOExercise of appraisal rights(+)30,000DART ↗
2025-11-03Jeil Pharmaceutical Co.,L10% shareholderAcquisition of new shares without compensation(+)15,754,284DART ↗
2025-10-28Cha Hyeon-juManaging directorExercise of appraisal rights(+)5,200DART ↗
2025-10-28SHIN JONGKILSenior managing directorExercise of appraisal rights(+)7,626DART ↗
2025-10-28Cha Hyeon-juManaging directorExercise of appraisal rights(+)5,200DART ↗
2025-10-28SHIN JONGKILSenior managing directorExercise of appraisal rights(+)7,626DART ↗
2025-10-28John KimCEOExercise of appraisal rights(+)40,000DART ↗
2025-10-13Cha Hyeon-juManaging directorAcquisition of new shares without compensation(+)108,600DART ↗
2025-10-13SHIN JONGKILSenior managing directorAcquisition of new shares without compensation(+)167,196DART ↗
2025-10-13Jeil Pharmaceutical Co.,L10% shareholderAcquisition of new shares without compensation(+)15,000,000DART ↗
2025-10-13SHIN JONGKILSenior managing directorAcquisition of new shares without compensation(+)292,908DART ↗
2025-10-13Cha Hyeon-juManaging directorAcquisition of new shares without compensation(+)128,712DART ↗
2025-10-13John KimCEOAcquisition of new shares without compensation(+)210,000DART ↗
2025-10-13Kim Jin-seongManaging directorAcquisition of new shares without compensation(+)36,000DART ↗
2025-09-16Cha Hyeon-juManaging directorExercise of appraisal rights(+)8,700DART ↗
2025-09-16SHIN JONGKILSenior managing directorExercise of appraisal rights(+)4,500DART ↗
2025-09-16John KimCEOExercise of appraisal rights(+)20,000DART ↗
2025-09-16Cha Hyeon-juManaging directorExercise of appraisal rights(+)8,700DART ↗
2025-09-16SHIN JONGKILSenior managing directorExercise of appraisal rights(+)4,500DART ↗
2025-09-16Kim Jin-seongManaging directorExercise of appraisal rights(+)12,000DART ↗
2025-04-15Cha Hyeon-juManaging directorExercise of appraisal rights(+)12,500DART ↗
2025-04-15SHIN JONGKILSenior managing directorExercise of appraisal rights(+)18,100DART ↗
2025-04-15John KimCEOStock options(+)50,000DART ↗
2025-04-15Cha Hyeon-juManaging directorExercise of appraisal rights(+)12,500DART ↗
2025-04-15SHIN JONGKILSenior managing directorExercise of appraisal rights(+)18,100DART ↗
2025-03-14Cha Hyeon-juManaging directorExercise of appraisal rights(+)15,000DART ↗
2025-03-14SHIN JONGKILSenior managing directorExercise of appraisal rights(+)30,000DART ↗
2025-03-14Cha Hyeon-juManaging directorExercise of appraisal rights(+)15,000DART ↗
2025-03-14SHIN JONGKILSenior managing directorExercise of appraisal rights(+)30,000DART ↗
2024-12-19Jeil Pharmaceutical Co.,L10% shareholderNew listing(+)5,000,000DART ↗
2024-12-19Cha Hyeon-juManaging director신규상장(+)6,704DART ↗
2024-12-19Jeil Pharmaceutical Co.,L10% shareholder신규상장(+)5,251,428DART ↗
2024-12-19SHIN JONGKILSenior managing director신규상장(+)41,904DART ↗